New daily shot could free patients from calcium pills
NCT ID NCT05387070
First seen Jan 21, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This phase 3 trial tested a daily injection called TransCon PTH in 81 adults with hypoparathyroidism, a condition where the body lacks parathyroid hormone, causing low calcium levels. The goal was to see if the drug could bring calcium levels back to normal and allow patients to stop taking high-dose vitamin D and calcium supplements. The study was double-blind for 26 weeks, then all participants received the drug in an open-label extension for up to 156 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.